John Lunec
John Lunec
Verified email at - Homepage
Cited by
Cited by
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
GJ Peters, HHJ Backus, S Freemantle, B Van Triest, G Codacci-Pisanelli, ...
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1587 (2-3 …, 2002
Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer
I Sigalas, AH Calvert, JJ Anderson, DE Neal, J Lunec
Nature medicine 2 (8), 912-917, 1996
Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma
RJ Gilbertson, RH Perry, PJ Kelly, ADJ Pearson, J Lunec
Cancer research 57 (15), 3272-3280, 1997
Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line
DA Tweddle, AJ Malcolm, N Bown, ADJ Pearson, J Lunec
Cancer research 61 (1), 8-13, 2001
Clinical and molecular stratification of disease risk in medulloblastoma
R Gilbertson, C Wickramasinghe, R Hernan, V Balaji, D Hunt, ...
British journal of cancer 85 (5), 705-712, 2001
Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay
K De Preter, F Speleman, V Combaret, J Lunec, G Laureys, BHJ Eussen, ...
Modern Pathology 15 (2), 159-166, 2002
The p53 pathway and its inactivation in neuroblastoma
DA Tweddle, ADJ Pearson, M Haber, MD Norris, C Xue, C Flemming, ...
Cancer letters 197 (1-2), 93-98, 2003
C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value
JK Mellon, J Lunec, C Wright, CHW Horne, P Kelly, DE Neal
The Journal of urology 155 (1), 321-326, 1996
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastomap53/MDM2/p14ARF Pathway in Neuroblastoma
J Carr-Wilkinson, K O'Toole, KM Wood, CC Challen, AG Baker, JR Board, ...
Clinical cancer research 16 (4), 1108-1118, 2010
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer
NC Levitt, FALM Eskens, KJ O’Byrne, DJ Propper, LJ Denis, SJ Owen, ...
Clinical Cancer Research 7 (7), 1912-1922, 2001
Small-molecule inhibitors of the MDM2-p53 protein− protein interaction based on an isoindolinone scaffold
IR Hardcastle, SU Ahmed, H Atkins, G Farnie, BT Golding, RJ Griffin, ...
Journal of medicinal chemistry 49 (21), 6209-6221, 2006
p53 is a direct transcriptional target of MYCN in neuroblastoma
L Chen, N Iraci, S Gherardi, LD Gamble, KM Wood, G Perini, J Lunec, ...
Cancer research 70 (4), 1377-1388, 2010
Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67
VM Tut, KL Braithwaite, B Angus, DE Neal, J Lunec, JK Mellon
British Journal of cancer 84 (2), 270-275, 2001
Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein− protein interaction: structure− activity studies leading to improved potency
IR Hardcastle, J Liu, E Valeur, A Watson, SU Ahmed, TJ Blackburn, ...
Journal of medicinal chemistry 54 (5), 1233-1243, 2011
Increased Frequency of Aberrations in the p53/MDM2/p14ARF Pathway in Neuroblastoma Cell Lines Established at Relapse
J Carr, E Bell, ADJ Pearson, UR Kees, H Beris, J Lunec, DA Tweddle
Cancer research 66 (4), 2138-2145, 2006
Quality assessment of genetic markers used for therapy stratification
IM Ambros, J Benard, M Boavida, N Bown, H Caron, V Combaret, ...
Journal of clinical oncology 21 (11), 2077-2084, 2003
MYCN oncoprotein targets and their therapeutic potential
E Bell, L Chen, T Liu, GM Marshall, J Lunec, DA Tweddle
Cancer letters 293 (2), 144-157, 2010
p53 cellular localization and function in neuroblastoma: evidence for defective G1 arrest despite WAF1 induction in MYCN-amplified cells
DA Tweddle, AJ Malcolm, M Cole, ADJ Pearson, J Lunec
The American journal of pathology 158 (6), 2067-2077, 2001
Analysis of the p53 tumor‐suppressor gene in hepatocellular carcinomas from Britain
C Challen, J Lunec, W Warren, J Collier, MF Bassendine
Hepatology 16 (6), 1362-1366, 1992
Isoindolinone-based inhibitors of the MDM2–p53 protein–protein interaction
IR Hardcastle, SU Ahmed, H Atkins, AH Calvert, NJ Curtin, G Farnie, ...
Bioorganic & medicinal chemistry letters 15 (5), 1515-1520, 2005
The system can't perform the operation now. Try again later.
Articles 1–20